NL300763I2 - - Google Patents
Download PDFInfo
- Publication number
- NL300763I2 NL300763I2 NL300763C NL300763C NL300763I2 NL 300763 I2 NL300763 I2 NL 300763I2 NL 300763 C NL300763 C NL 300763C NL 300763 C NL300763 C NL 300763C NL 300763 I2 NL300763 I2 NL 300763I2
- Authority
- NL
- Netherlands
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86929906P | 2006-12-08 | 2006-12-08 | |
US96644907P | 2007-08-28 | 2007-08-28 | |
PCT/US2007/085304 WO2008073687A2 (en) | 2006-12-08 | 2007-11-20 | Compounds and compositions as protein kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NL300763I2 true NL300763I2 (nl) | 2016-02-09 |
NL300763I1 NL300763I1 (nl) | 2016-02-09 |
Family
ID=39370882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL300763C NL300763I1 (nl) | 2006-12-08 | 2015-10-07 |
Country Status (30)
Country | Link |
---|---|
EP (1) | EP2091918B1 (nl) |
JP (3) | JP5208123B2 (nl) |
KR (1) | KR101149295B1 (nl) |
CN (2) | CN103641816A (nl) |
AU (3) | AU2007333394C1 (nl) |
BR (1) | BRPI0720264B1 (nl) |
CA (1) | CA2671744C (nl) |
CO (1) | CO6231028A2 (nl) |
CR (1) | CR10832A (nl) |
CY (1) | CY2015043I2 (nl) |
DK (1) | DK2091918T3 (nl) |
EA (1) | EA017405B9 (nl) |
EC (1) | ECSP099500A (nl) |
FR (1) | FR15C0058I2 (nl) |
GT (1) | GT200900147A (nl) |
HU (1) | HUS1500049I1 (nl) |
IL (1) | IL198936A0 (nl) |
LT (1) | LTC2091918I2 (nl) |
MA (1) | MA30923B1 (nl) |
ME (1) | ME00811B (nl) |
MX (1) | MX2009006081A (nl) |
NL (1) | NL300763I1 (nl) |
NO (3) | NO338069B1 (nl) |
PL (1) | PL2091918T3 (nl) |
PT (1) | PT2091918E (nl) |
SM (1) | SMP200900058B (nl) |
SV (1) | SV2009003290A (nl) |
TN (1) | TN2009000225A1 (nl) |
WO (1) | WO2008073687A2 (nl) |
ZA (1) | ZA200903601B (nl) |
Families Citing this family (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008045663A2 (en) * | 2006-10-06 | 2008-04-17 | Kalypsys, Inc. | Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents |
TWI432427B (zh) | 2006-10-23 | 2014-04-01 | Cephalon Inc | 作為ALK及c-MET抑制劑之2,4-二胺基嘧啶之融合雙環衍生物 |
AU2007333394C1 (en) * | 2006-12-08 | 2011-08-18 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
WO2008079719A1 (en) * | 2006-12-19 | 2008-07-03 | Genentech, Inc. | Pyrimidine kinase inhibitors |
TW200902010A (en) | 2007-01-26 | 2009-01-16 | Smithkline Beecham Corp | Anthranilamide inhibitors of aurora kinase |
DK2134689T3 (da) | 2007-03-16 | 2014-06-30 | Scripps Research Inst | Inhibitorer af fokal adhæsionskinase |
TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二(芳胺基)芳基化合物 |
WO2009032668A2 (en) * | 2007-08-28 | 2009-03-12 | Irm Llc | 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors |
WO2009032694A1 (en) * | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
MX2010002772A (es) | 2007-09-21 | 2010-03-31 | Array Biopharma Inc | Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucocinasa para el tratamiento de diabetes mellitus. |
EP2249650A4 (en) * | 2008-02-19 | 2012-01-11 | Glaxosmithkline Llc | ANILINOPYRIDINE AS A FAK HEMMER |
MX2010010968A (es) | 2008-04-07 | 2010-10-26 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa de proteina. |
WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
CA2723961C (en) | 2008-05-21 | 2017-03-21 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
JP5551689B2 (ja) | 2008-06-17 | 2014-07-16 | アストラゼネカ アクチボラグ | ピリジン化合物 |
KR20110020940A (ko) * | 2008-06-25 | 2011-03-03 | 아이알엠 엘엘씨 | 키나제 억제제로서의 피리미딘 유도체 |
US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
UY31929A (es) * | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
BRPI0914682B8 (pt) * | 2008-06-27 | 2021-05-25 | Avila Therapeutics Inc | compostos de heteroarila e composições compreendendo os referidos compostos |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
JP2012501981A (ja) * | 2008-09-03 | 2012-01-26 | バイエル・クロップサイエンス・アーゲー | 殺菌剤としてのヘテロ環置換アニリノピリミジン類 |
TW201100427A (en) | 2009-03-31 | 2011-01-01 | Arqule Inc | Substituted heterocyclic compounds |
CN102482277B (zh) * | 2009-05-05 | 2017-09-19 | 达纳-法伯癌症研究所有限公司 | 表皮生长因子受体抑制剂及治疗障碍的方法 |
PL2428508T3 (pl) | 2009-05-08 | 2016-05-31 | Astellas Pharma Inc | Diaminoheterocykliczny związek karboksyamidowy |
MX2011012632A (es) * | 2009-05-27 | 2012-03-06 | Abbott Lab | Inhibidores de actividad de cinasa tipo pirimidina. |
EP2467142B1 (en) | 2009-08-17 | 2016-09-21 | Memorial Sloan-Kettering Cancer Center | 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders |
RU2012114902A (ru) | 2009-09-16 | 2013-10-27 | Авила Терапьютикс, Инк. | Конъюгаты и ингибиторы протеинкиназы |
MA33926B1 (fr) | 2009-12-17 | 2013-01-02 | Merck Sharp & Dohme | Aminopyrimidines en tant qu'inhibiteurs de la syk |
EP2512246B1 (en) | 2009-12-17 | 2015-09-30 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
CA2785738A1 (en) | 2009-12-30 | 2011-07-07 | Avila Therapeutics, Inc. | Ligand-directed covalent modification of protein |
JP2013522215A (ja) | 2010-03-09 | 2013-06-13 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 組合わせ抗癌療法 |
CA2797947C (en) | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
KR20130099040A (ko) | 2010-08-10 | 2013-09-05 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Btk 억제제의 베실레이트 염 |
BR112013010564B1 (pt) | 2010-11-01 | 2021-09-21 | Celgene Car Llc | Compostos heterocíclicos e composições compreendendo os mesmos |
JP5956999B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | ヘテロアリール化合物およびその使用 |
ES2665013T3 (es) | 2010-11-10 | 2018-04-24 | Celgene Car Llc | Inhibidores de EGFR selectivos de mutante y usos de los mismos |
HUE046617T2 (hu) | 2010-11-10 | 2020-03-30 | Genentech Inc | Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok |
EP3453708B8 (en) * | 2010-12-17 | 2022-03-16 | Novartis AG | Process for the preparation of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine di-hydrochloride |
WO2012097479A1 (en) * | 2011-01-21 | 2012-07-26 | Abbott Laboratories | Bicyclic inhibitors of anaphastic lymphoma kinase |
CN103458881B (zh) | 2011-02-02 | 2015-08-12 | Irm责任有限公司 | Alk抑制剂的使用方法 |
GB201104267D0 (en) * | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
CN103501612B (zh) | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物 |
CA2834604A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
WO2012154518A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
US9120785B2 (en) | 2011-05-10 | 2015-09-01 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as Syk inhibitors |
US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
CA2861010A1 (en) | 2012-01-13 | 2013-07-18 | Xiao Xu | Heterocyclic compounds and uses as anticancer agents |
US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
EP2825042B1 (en) | 2012-03-15 | 2018-08-01 | Celgene CAR LLC | Salts of an epidermal growth factor receptor kinase inhibitor |
BR112014022789B1 (pt) | 2012-03-15 | 2022-04-19 | Celgene Car Llc | Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo |
FR2988722B1 (fr) | 2012-04-03 | 2014-05-09 | Sanofi Sa | Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques |
WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
CN104854101B (zh) | 2012-11-06 | 2018-05-01 | 上海复尚慧创医药研究有限公司 | Alk激酶抑制剂 |
BR112015010396A2 (pt) * | 2012-11-07 | 2017-07-11 | Novartis Ag | terapia de combinação |
WO2014100748A1 (en) | 2012-12-21 | 2014-06-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
CN104109149B (zh) | 2013-04-22 | 2018-09-28 | 苏州泽璟生物制药有限公司 | 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物 |
JP2016522247A (ja) | 2013-06-18 | 2016-07-28 | ノバルティス アーゲー | 組合せ医薬 |
CA2917735C (en) * | 2013-07-11 | 2017-04-18 | Betta Pharmaceuticals Co., Ltd | Protein tyrosine kinase modulators and methods of use |
CN117486865A (zh) | 2013-07-11 | 2024-02-02 | 艾森医药公司 | 嘧啶衍生物作为激酶抑制剂 |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
CN106029099A (zh) * | 2013-08-28 | 2016-10-12 | 诺华股份有限公司 | 用于治疗细胞增殖性疾病的alk抑制剂与cdk抑制剂的组合 |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
CN105848682A (zh) * | 2013-12-23 | 2016-08-10 | 诺华股份有限公司 | 药物组合 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
CN106103484B (zh) | 2014-03-14 | 2021-08-20 | 诺华股份有限公司 | 针对lag-3的抗体分子及其用途 |
CA2948621A1 (en) | 2014-05-13 | 2015-11-19 | Memorial Sloan Kettering Cancer Center | Hsp70 modulators and methods for making and using the same |
AU2015265470A1 (en) * | 2014-05-29 | 2016-11-24 | Novartis Ag | Ceritinib formulation |
CN105272921A (zh) * | 2014-06-09 | 2016-01-27 | 江苏奥赛康药业股份有限公司 | 一种制备Ceritinib的方法及其中间体化合物 |
CN103992262B (zh) * | 2014-06-12 | 2015-11-11 | 苏州明锐医药科技有限公司 | 塞瑞替尼及其中间体的制备方法 |
US10053458B2 (en) * | 2014-06-17 | 2018-08-21 | Korea Research Institute Of Chemical Technology | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
CN107108586B (zh) | 2014-09-29 | 2020-07-10 | 山东轩竹医药科技有限公司 | 多环类间变性淋巴瘤激酶抑制剂 |
KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CU20170052A7 (es) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
US20170252335A1 (en) | 2014-10-17 | 2017-09-07 | Novartis Ag | Combination of Ceritinib with an EGFR Inhibitor |
WO2016098070A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
WO2016098042A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders |
EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
CN105777616B (zh) * | 2014-12-26 | 2018-12-07 | 上海医药工业研究院 | 色瑞替尼的合成中间体及其制备方法 |
CN105777617B (zh) * | 2014-12-26 | 2018-11-06 | 上海医药工业研究院 | 色瑞替尼的合成中间体及其制备方法 |
US9296721B1 (en) * | 2015-02-13 | 2016-03-29 | Yong Xu | Method for preparing ALK inhibitor ceritinib |
EP3778604A1 (en) * | 2015-02-13 | 2021-02-17 | Dana Farber Cancer Institute, Inc. | Lrrk2 inhibitors and methods of making and using the same |
CN107531672A (zh) | 2015-03-04 | 2018-01-02 | 诺华股份有限公司 | 制备嘧啶衍生物及其中间体的化学工艺 |
MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
CN106146387A (zh) * | 2015-03-30 | 2016-11-23 | 湖北生物医药产业技术研究院有限公司 | Alk抑制剂的制备方法 |
WO2016167511A2 (ko) * | 2015-04-14 | 2016-10-20 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
KR101772134B1 (ko) | 2015-04-14 | 2017-08-29 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
WO2017016529A1 (en) | 2015-07-28 | 2017-02-02 | Zentiva, K.S. | Solid forms of ceritinib free base |
EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
SI3317301T1 (sl) | 2015-07-29 | 2021-10-29 | Novartis Ag | Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3 |
CZ2015613A3 (cs) | 2015-09-09 | 2017-03-22 | Zentiva, K.S. | Způsob přípravy Ceritinibu |
MX2018003590A (es) * | 2015-09-25 | 2018-11-29 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos y metodos para la inhibicion de jak. |
MX2018004332A (es) | 2015-10-09 | 2019-01-10 | Acea Therapeutics Inc | Sales farmaceuticas, formas fisicas y composiciones de inhibidores de pirrolopirimidina cinasa, y metodos para fabricar las mismas. |
CN106565593B (zh) * | 2015-10-10 | 2019-03-01 | 常州市勇毅生物药业有限公司 | 一种色瑞替尼中间体的制备方法 |
BR112018008904A2 (pt) | 2015-11-03 | 2018-11-27 | Janssen Biotech Inc | anticorpos que se ligam especificamente a tim-3 e seus usos |
CN106699743B (zh) * | 2015-11-05 | 2020-06-12 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类衍生物及其用途 |
JP6634157B2 (ja) * | 2015-11-26 | 2020-01-22 | ノバルティス アーゲー | ジアミノピリジン誘導体 |
CA3007671A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
WO2017153932A1 (en) | 2016-03-10 | 2017-09-14 | Novartis Ag | Strn-alk fusion as a therapeutic target in gastric cancer |
WO2017175111A1 (en) | 2016-04-04 | 2017-10-12 | Novartis Ag | Strn-alk fusion as a therapeutic target in colorectal cancer |
EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
KR101937529B1 (ko) * | 2016-07-26 | 2019-01-14 | 한국화학연구원 | 신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
CA3048340A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
MX2019010086A (es) | 2017-02-27 | 2020-02-12 | Novartis Ag | Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1. |
BR112019020840A2 (pt) | 2017-04-07 | 2020-04-28 | Acea Therapeutics Inc | sais farmacêuticos, formas físicas e composições de inibidores da pirrolopirimidina quinase e métodos de produção dos mesmos |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
CN110092759A (zh) * | 2018-01-31 | 2019-08-06 | 陆柯潮 | 作为抗肿瘤药物的5-氯-2,4-嘧啶衍生物 |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
CA3102214A1 (en) * | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Ligands to cereblon (crbn) |
CN109593065A (zh) * | 2018-12-03 | 2019-04-09 | 重庆医科大学 | 一类hdac/alk双靶点抑制剂及其制备方法与应用 |
TWI769470B (zh) * | 2019-06-25 | 2022-07-01 | 大陸商蘇州亞盛藥業有限公司 | 用於治療疾病的fak抑制劑和btk抑制劑的組合 |
WO2021003417A1 (en) | 2019-07-03 | 2021-01-07 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
CN112538072B (zh) * | 2019-09-21 | 2024-02-06 | 齐鲁制药有限公司 | 氨基嘧啶类egfr抑制剂 |
GB201915618D0 (en) | 2019-10-28 | 2019-12-11 | Univ Oslo | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
WO2021098883A1 (zh) * | 2019-11-21 | 2021-05-27 | 浙江同源康医药股份有限公司 | 用作egfr激酶抑制剂的化合物及其应用 |
WO2021111311A2 (ko) * | 2019-12-03 | 2021-06-10 | 삼진제약주식회사 | 국소 부착 키나아제 저해제로서 신규한 아다만탄 유도체 |
CA3161667A1 (en) * | 2019-12-16 | 2021-06-24 | Pil Ho Kim | Novel pyrimidine derivative and use thereof |
EP4129996A4 (en) * | 2020-03-23 | 2023-07-12 | Qilu Pharmaceutical Co., Ltd. | NEW EGFR AMINOPYRIMIDINE INHIBITOR |
CN111484484B (zh) * | 2020-04-13 | 2021-11-23 | 沈阳药科大学 | 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用 |
WO2023106881A1 (ko) * | 2021-12-09 | 2023-06-15 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약학 조성물 |
TW202333667A (zh) * | 2021-12-13 | 2023-09-01 | 大陸商希格生科(深圳)有限公司 | 嘧啶或吡啶類衍生物及其醫藥用途 |
CN115368366A (zh) * | 2022-08-02 | 2022-11-22 | 江苏省中医药研究院 | 嘧啶并吡唑类化合物及其应用 |
CN115448906B (zh) * | 2022-09-26 | 2024-04-02 | 深圳大学 | 一种2-苯胺基嘧啶类衍生物及其制备方法与应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT874846E (pt) * | 1995-11-01 | 2003-08-29 | Novartis Ag | Derivados de purina e processos para a sua preparacao |
DE69933680T2 (de) * | 1998-08-29 | 2007-08-23 | Astrazeneca Ab | Pyrimidine verbindungen |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
WO2001060816A1 (en) * | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
FR2818642B1 (fr) * | 2000-12-26 | 2005-07-15 | Hoechst Marion Roussel Inc | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion |
AU2002245709A1 (en) * | 2001-03-23 | 2002-10-08 | Bayer Corporation | Rho-kinase inhibitors |
AR035791A1 (es) * | 2001-03-23 | 2004-07-14 | Bayer Corp | Compuesto n,n-diheterociclico de amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y proceso para la preparacion del compuesto |
AU2003202263A1 (en) * | 2002-01-10 | 2003-07-30 | Bayer Healthcare Ag | Roh-kinase inhibitors |
GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
GB0319227D0 (en) * | 2003-08-15 | 2003-09-17 | Novartis Ag | Organic compounds |
GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
CN1798734A (zh) * | 2003-04-04 | 2006-07-05 | Irm责任有限公司 | 作为蛋白激酶抑制剂的新化合物和组合物 |
PL1660458T3 (pl) * | 2003-08-15 | 2012-07-31 | Novartis Ag | 2,4-pirymidynodwuaminy stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego |
MXPA06001758A (es) * | 2003-08-15 | 2006-08-11 | Irm Llc | Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk. |
GB0407723D0 (en) * | 2004-04-05 | 2004-05-12 | Novartis Ag | Organic compounds |
EP1598343A1 (de) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
EP1841760B1 (en) * | 2004-12-30 | 2011-08-10 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
TWI432427B (zh) * | 2006-10-23 | 2014-04-01 | Cephalon Inc | 作為ALK及c-MET抑制劑之2,4-二胺基嘧啶之融合雙環衍生物 |
AU2007333394C1 (en) * | 2006-12-08 | 2011-08-18 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
-
2007
- 2007-11-20 AU AU2007333394A patent/AU2007333394C1/en active Active
- 2007-11-20 CN CN201310573341.3A patent/CN103641816A/zh active Pending
- 2007-11-20 MX MX2009006081A patent/MX2009006081A/es active IP Right Grant
- 2007-11-20 JP JP2009540379A patent/JP5208123B2/ja active Active
- 2007-11-20 KR KR1020097014175A patent/KR101149295B1/ko active Protection Beyond IP Right Term
- 2007-11-20 DK DK07864693.2T patent/DK2091918T3/en active
- 2007-11-20 ME MEP-2009-216A patent/ME00811B/me unknown
- 2007-11-20 EA EA200970557A patent/EA017405B9/ru not_active IP Right Cessation
- 2007-11-20 BR BRPI0720264-4A patent/BRPI0720264B1/pt active IP Right Grant
- 2007-11-20 CN CN201310574409.XA patent/CN103641833A/zh active Pending
- 2007-11-20 CA CA2671744A patent/CA2671744C/en active Active
- 2007-11-20 PL PL07864693T patent/PL2091918T3/pl unknown
- 2007-11-20 PT PT78646932T patent/PT2091918E/pt unknown
- 2007-11-20 EP EP07864693.2A patent/EP2091918B1/en active Active
- 2007-11-20 WO PCT/US2007/085304 patent/WO2008073687A2/en active Application Filing
-
2009
- 2009-05-25 IL IL198936A patent/IL198936A0/en active Protection Beyond IP Right Term
- 2009-05-25 ZA ZA2009/03601A patent/ZA200903601B/en unknown
- 2009-05-27 MA MA31924A patent/MA30923B1/fr unknown
- 2009-05-28 CR CR10832A patent/CR10832A/es unknown
- 2009-06-03 GT GT200900147A patent/GT200900147A/es unknown
- 2009-06-03 TN TNP2009000225A patent/TN2009000225A1/fr unknown
- 2009-06-08 SV SV2009003290A patent/SV2009003290A/es unknown
- 2009-06-30 NO NO20092472A patent/NO338069B1/no active Protection Beyond IP Right Term
- 2009-07-02 SM SM200900058T patent/SMP200900058B/it unknown
- 2009-07-08 CO CO09070739A patent/CO6231028A2/es active IP Right Grant
- 2009-07-08 EC EC2009009500A patent/ECSP099500A/es unknown
-
2010
- 2010-08-09 AU AU2010210018A patent/AU2010210018B2/en not_active Ceased
- 2010-08-09 AU AU2010210019A patent/AU2010210019C1/en not_active Ceased
-
2012
- 2012-07-06 JP JP2012152703A patent/JP5513558B2/ja active Active
-
2013
- 2013-02-19 JP JP2013030284A patent/JP2013144683A/ja active Pending
-
2015
- 2015-08-26 FR FR15C0058C patent/FR15C0058I2/fr active Active
- 2015-09-29 LT LTPA2015034C patent/LTC2091918I2/lt unknown
- 2015-10-02 HU HUS1500049C patent/HUS1500049I1/hu unknown
- 2015-10-07 NL NL300763C patent/NL300763I1/nl unknown
- 2015-11-02 CY CY2015043C patent/CY2015043I2/el unknown
-
2016
- 2016-02-29 NO NO20160333A patent/NO20160333A1/no not_active Application Discontinuation
- 2016-08-10 NO NO2016014C patent/NO2016014I2/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2016014I1 (nl) | ||
CN100532764C9 (zh) | 前移旋转避让型载车装置 | |
CH2121272H1 (nl) | ||
BY9789C1 (nl) | ||
CN300725934S (zh) | 童装(3833) | |
CN300725918S (zh) | 童装(3748) | |
CN300725922S (zh) | 童装(3773) | |
CN300725916S (zh) | 童装(3732) | |
CN300725928S (zh) | 童装(3809) | |
CN300725915S (zh) | 童装(3728) | |
CN300725929S (zh) | 童装(3811) | |
CN300725921S (zh) | 童装(3771) | |
CN300725930S (zh) | 童装(3813) | |
CN300725927S (zh) | 童装(3795) | |
CN300725931S (zh) | 童装(3815) | |
CN300725914S (zh) | 童装(3714) | |
CN300725913S (zh) | 童装(3712) | |
CN300725912S (zh) | 童装(3706) | |
CN300725932S (zh) | 童装(3829) | |
CN300725933S (zh) | 童装(3831) | |
CN300725924S (zh) | 童装(3789) | |
CN300725935S (zh) | 童装裤子(3835) | |
CN300725926S (zh) | 童装(3793) | |
CN300725917S (zh) | 童装(3734) | |
CN300728507S (zh) | 棺材(2) |